Evoke pharma inc (EVOK)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Sep'12
Operating expenses:
Research and development

463

641

822

1,205

746

695

625

1,388

1,385

1,631

2,717

2,017

770

1,502

1,339

2,095

2,015

1,708

1,837

2,188

2,419

2,176

3,088

2,874

1,852

-

-

-

-

-

Research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

78

130

110

337

General and administrative

1,329

782

814

918

1,223

1,073

897

917

1,032

1,027

984

871

1,209

822

830

802

1,137

842

819

976

1,025

738

732

616

1,070

944

406

72

221

140

Total operating expenses

1,793

1,424

1,636

2,123

1,969

1,768

1,522

2,306

2,417

2,659

3,701

2,889

1,980

2,324

2,169

2,897

3,152

2,551

2,657

3,164

3,445

2,914

3,821

3,491

2,922

1,580

485

203

332

477

Loss from operations

-1,793

-1,424

-1,636

-2,123

-1,969

-1,768

-1,522

-2,306

-2,417

-2,659

-3,701

-2,889

-1,980

-2,324

-2,169

-2,897

-3,152

-2,551

-2,657

-3,164

-3,445

-2,914

-3,821

-3,491

-2,922

-1,580

-485

-203

-332

-477

Other income:
Interest income

3

5

8

9

4

7

3

2

1

1

2

1

0

0

-123

-72

-72

-

-77

-

-

-

-

-

-

-

-

-

-

-

Financing costs related to warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

533

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

1

0

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

39

40

39

10

Gain from change in fair value of warrant liability

-

-

-

-

-

0

0

0

-433

-2,349

1,544

-1,261

3,072

-

198

-

-

-

-

-

-

-

-

-

-

0

-39

-3

124

-1

Interest income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1

3

4

-

-

-

-

-

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

5

58

36

-

-

-

-

-

Total other income

3

5

8

9

4

7

3

2

434

2,350

-1,541

1,263

-3,071

797

-855

-72

-72

-73

-77

-76

-75

-5

-4

-55

-32

-35

-0

-36

-161

-8

Net loss

-1,790

-1,418

-1,628

-2,114

-1,965

-1,760

-1,519

-2,303

-1,982

-308

-5,243

-1,625

-5,052

-1,527

-3,025

-2,970

-3,225

-2,624

-2,735

-3,241

-3,520

-2,919

-3,825

-3,547

-2,955

-1,616

-485

-239

-493

-486

Net loss per share of common stock, basic

-

-

-

-

-

-

-

-

-

-0.02

-0.34

-0.11

-

-

-0.29

-0.41

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss per share of common stock, diluted

-

-

-

-

-

-

-

-

-

-0.07

-0.34

-0.13

-

-

-0.29

-0.41

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted-average shares used to compute basic net loss per share

-

-

-

-

-

-

-

-

-

15,368

15,351

15,343

-

-

10,614

7,217

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted-average shares used to compute diluted net loss per share

-

-

-

-

-

-

-

-

-

15,503

15,351

15,420

-

-

10,614

7,217

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss per share of common stock, basic and diluted

-0.07

-0.06

-0.07

-0.09

-0.11

-0.10

-0.09

-0.14

-0.13

-

-

-

-0.37

-

-

-

-0.45

-0.35

-0.42

-0.52

-0.58

-0.49

-0.63

-0.59

-0.49

-0.14

-0.41

-0.21

-0.44

-0.43

Weighted-average shares used to compute basic and diluted net loss per share

24,439

24,313

24,128

23,258

17,484

17,427

17,129

16,425

15,427

-

-

-

13,528

-

-

-

7,168

7,131

6,494

6,212

6,103

6,045

6,054

6,027

6,002

6,011

1,190

1,137

1,133

1,125